x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Prova Education

Prova Education designs educational programs that address a broad spectrum of gaps in awareness, attitudes, skills, and competencies related to guideline-based care and evolving disease management options. Its mission is to serve as an innovative and relevant resource for clinical content that promotes change in practice and patient outcomes.

science & medicine medicine

All Episodes

00:00:00

Individualizing Frontline Treatment

Prova Education ·

2023/07/15

Host: Alex Herrera, MD Guest: Alison J. Moskowitz, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large

en

00:00:00

Clinical Implications of Bispecific Antibodies and...

Prova Education ·

2023/07/15

Host: Kami Maddocks, MD Guest: Matthew J. Matasar, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large

en

00:00:00

Patient Selection for ADCs in First-Line DLBCL

Prova Education ·

2023/07/15

Host: John P. Leonard, MD Guest: Sarah Rutherford, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large

en

00:00:00

Lessening Glaucoma Treatment Burden: Clinical Cases...

Prova Education ·

2023/06/23

Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive

en

00:00:00

Lessening Glaucoma Treatment Burden:...

Prova Education ·

2023/06/23

Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive

en

00:00:00

Lessening Glaucoma Treatment Burden:...

Prova Education ·

2023/06/23

Guest: Davinder S. Grover, MD, MPH First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally

en

00:00:00

Lessening Glaucoma Treatment Burden with Topical...

Prova Education ·

2023/06/23

Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive

en

00:00:00

Advances in Glaucoma Treatment: MIGS (Part 1)

Prova Education ·

2023/06/23

Guest: Davinder S. Grover, MD, MPH First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally

en

00:00:00

Advances in Glaucoma Treatment: Novel Topical Therapies

Prova Education ·

2023/06/23

Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive

en

00:00:00

Advances in Glaucoma Treatment: MIGS (Part 2)

Prova Education ·

2023/06/23

Guest: Davinder S. Grover, MD, MPH First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally

en

00:00:00

Lessening Glaucoma Treatment Burden with Topical...

Prova Education ·

2023/06/23

Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive

en

00:00:00

Lessening Glaucoma Treatment Burden: Clinical Cases...

Prova Education ·

2023/06/23

Guest: Davinder S. Grover, MD, MPH First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally

en

00:00:00

PAH Clinical Consult: Getting to the Heart of PAH

Prova Education ·

2023/06/20

Host: Vallerie V. McLaughlin, MD Guest: Rajan Saggar, MD Diagnosis of pulmonary arterial hypertension, or PAH, may be delayed because symptoms are nonspecific. And while there have been many advances in terms of available treatments, it remains imperative that providers perform a thorough risk assessment on each patient. In addition, it’s necessary to develop both a multidimensional approach to caring for patients with PAH and a communication plan to use with patients, care

en

00:00:00

Patient-Centered Communications and Shared...

Prova Education ·

2023/06/16

Host: Charles P. Vega, MD Obesity and overweight have reached epidemic status in the US. While safe and effective treatment options are available, it remains a challenge for clinicians to initiate conversations about weight with their patients. Learn how to open channels of communication with your patients by watching Dr. Charles Vega interact with a 42-year-old patient using shared decision-making.

en

00:00:00

HPV Vaccination Rates in Mid-Adult and High-Risk...

Prova Education ·

2023/06/15

Host: Anna Giuliano, PhD Guest: Joel Heidelbaugh, MD HPV vaccination guidance for mid-aged adults (27 to 45 years old) was updated by the CDC in 2019. Unfortunately, very few individuals in the US in this age range have ever been vaccinated for HPV, despite the risk for acquiring an HPV infection that can potentially progress to cancer, most notably oropharyngeal, cervical, and anorectal. Join us as Drs. Anna Giuliano and Joel Heidelbaugh discuss strategies for improving HPV

en

00:00:00

Overcoming Barriers for Vulnerable Patients with...

Prova Education ·

2023/06/06

Host: Charles P. Vega, MD Guest: Sharon D. Solomon, MD New treatments are available to manage diabetic macular edema (DME) that have the added benefit of reducing treatment burden. This can level the playing field and benefit patients who are less likely to access routine healthcare. Tune in to hear Dr. Sharon Solomon and Dr. Charles Vega discuss how the latest clinical data measure up by prolonging treatment intervals and how retina specialists are now better equipped to care for

en

00:00:00

Strategies to Reduce Treatment Burden for Vulnerable...

Prova Education ·

2023/06/06

Host: Charles P. Vega, MD Guest: Pradeep S. Prasad, MD, MBA Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Pradeep Prasad and Dr. Charles Vega are doing to curb the negative outcomes of diabetic eye disease in their patients at high risk for vision loss.

en

00:00:00

Will you ACCELERATE Patient Outcomes?

Prova Education ·

2023/05/31

Host: Corey Casper, MD, MPH Guest: Sudipto Mukherjee, MD, PhD, MPH Guest: Jovanna De La Pena This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and

en

00:00:00

Case Challenge in Obesity Medical Management

Prova Education ·

2023/05/26

Host: Charles P. Vega, MD Guest: Donna Ryan, MD Addressing the health issues of your patients with obesity can present a challenge. How can you initiate the conversation and effectively emphasize the benefits of weight loss? Join Drs. Charles Vega and Donna Ryan as they review a case of obesity and use evidence-based medicine to develop a patient-centric treatment plan.

en

00:00:00

What You Need to Know About Weight-Loss Medications

Prova Education ·

2023/05/26

Host: Charles P. Vega, MD Guest: Donna Ryan, MD Obesity is a chronic, progressive disease which has often been overlooked by physicians, leaving a considerable proportion of people with obesity underdiagnosed and inappropriately managed. Join Drs. Charles Vega and Donna Ryan as they break down the pathophysiology of obesity and discuss currently available weight-loss medications.

en

134 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事